Skip to main content
main-content

01.10.2010 | American Society of Breast Surgeons | Sonderheft 3/2010

Annals of Surgical Oncology 3/2010

Molecular Detection of Micrometastatic Breast Cancer in Histopathology—Negative Axillary Lymph Nodes Fails to Predict Breast Cancer Recurrence: A Final Analysis of a Prospective Multi-Institutional Cohort Study

Zeitschrift:
Annals of Surgical Oncology > Sonderheft 3/2010
Autoren:
MD Carla Suzanne Fisher, MD David J. Cole, PhD Michael Mitas, PhD Elizabeth Garrett-Meyer, MD John S. Metcalf, MD William E. Gillanders, MD Kaidi Mikhitarian, MD Marshall M. Urist, MD G. Bruce Mann, MD Gerard Doherty, MD Virginia M. Herrmann, MD Arnold D. Hill, MD Oleg Eremin, MD, PhD Mohamed El-Sheemy, MD Richard K. Orr, MD Alvaro A. Valle, MD Michael A. Henderson, MD Robert L. Dewitty, MD Sonia L. Sugg, MD Eric Frykberg, MD Karen Yeh, MD Richard M. Bell, MD Megan K. Baker
Wichtige Hinweise
This study was support by the grant from Department of Defense N00014-99-1-0784.

Abstract

Background

To address the clinical relevance of molecular detection of occult breast cancer in sentinel lymph nodes and nonsentinel axillary lymph nodes (ALN), we initiated the Minimally Invasive Molecular Staging of Breast Cancer (MIMS) trial, a multi-institutional prospective cohort study. This trial represents the first prospective cohort study in which a multimarker, real-time reverse transcription polymerase chain reaction (RT-PCR) analysis was applied to the detection of breast cancer micrometastases in ALN.

Materials and Methods

Sentinel and/or nonsentinel ALN from 501 breast cancer subjects with T1–T3 primary tumors were analyzed by standard histopathology and multimarker, real-time RT-PCR analysis. Seven breast cancer-associated genes (mam, mamB, PIP, CK19, muc1, PSE, and CEA) known to be overexpressed in metastatic breast cancer compared with control lymph nodes were used. Follow-up data were collected for 5 years.

Results

Of the 501 breast cancer subjects enrolled, 348 were node negative and completed the 5-year follow-up. Of these patients (n = 94), 27% demonstrated evidence of molecular overexpression. The 5-year relapse-free survival rate was 95.4% (95% confidence interval [95% CI], 92.4–97.2%). No single gene or combination of study genes was predictive of recurrence.

Conclusions

The genes in this study panel failed to be predictive of clinical relapse. This may be a function of several factors: the low event rate at 5 years, the particular gene set, the methodology used for detection/analysis or that our original hypothesis was wrong and that the presence of positive marker signal by real-time RT-PCR is not associated with a worsened clinical outcome.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Sonderheft 3/2010

Annals of Surgical Oncology 3/2010 Zur Ausgabe

American Society of Breast Surgeons

Controversies in Breast Surgery

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise